OMERS ADMINISTRATION Corp Buys Shares of 168,300 Immunic, Inc. $IMUX

OMERS ADMINISTRATION Corp purchased a new position in Immunic, Inc. (NASDAQ:IMUX) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 168,300 shares of the company’s stock, valued at approximately $187,000.

A number of other hedge funds also recently modified their holdings of IMUX. Renaissance Technologies LLC acquired a new position in shares of Immunic in the 1st quarter valued at approximately $1,020,000. Simplify Asset Management Inc. bought a new stake in Immunic during the 1st quarter worth approximately $487,000. Seven Fleet Capital Management LP acquired a new stake in Immunic during the 4th quarter worth approximately $83,000. Connective Capital Management LLC acquired a new stake in Immunic during the 4th quarter worth approximately $161,000. Finally, XTX Topco Ltd bought a new position in Immunic in the fourth quarter valued at approximately $120,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on IMUX. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday. Roth Capital restated a “buy” rating and set a $19.00 price objective on shares of Immunic in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Finally, B. Riley Financial reduced their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $47.57.

Immunic Stock Performance

NASDAQ:IMUX opened at $13.97 on Friday. Immunic, Inc. has a 52-week low of $5.06 and a 52-week high of $15.84. The company has a market cap of $190.27 million, a P/E ratio of -2.50 and a beta of 1.37. The stock’s 50-day simple moving average is $14.29 and its 200 day simple moving average is $11.47.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, equities analysts predict that Immunic, Inc. will post -4.54 earnings per share for the current fiscal year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.